Photo of Takao Ohnuma

Takao Ohnuma

  • PROFESSOR Medicine, Hematology and Medical Oncology
  • PROFESSOR Oncological Sciences
Print ProfilePrint Profile

Education

  • MD, Tohoku University Medical School

  • Residency, Rotating
    Lincoln Hospital

  • Residency, Internal Medicine
    Coler Memorial Hospital

  • Residency, Internal Medicine
    Roswell Park Memorial Institute

  • Fellowship, Medical Oncology
    Roswell Park Memorial Institute

Research

Dr. Ohnuma's research laboratory, for a number of years, has focused on carrying out cellular, biochemical and molecular pharmacological investigations of cancer therapeutics. During the past year, two projects have been emphasized, the development of ribozyme strategy against deletion-mutant EGFR in the treatment of human glioblastoma multiforme, and the examination of reovirus as an anticancer agent.

Publications

Plasse T, Ohnuma T, Brooks S, Saponara E, Holland J, Biller H. Bleomycin infusion followed by cyclophosphamide, methotrexate and fluorouracil in advanced squamous carcinoma of the head and neck. Cancer 1984; 53: 841-843.

Kobayashi H, Takemura Y, Holland JF, Ohnuma T. Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: Mechanism of inoculum effect. Biochem Pharmacol 1998; 55: 1229-1234.

Wang FS, Kobayashi H, Liang KW, Holland JF, Ohnuma T. Retrovirus-mediated anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum Gene Ther 1999; 10: 1185-1195.

Kobayashi H, Takemura Y, Wang FS, Oka T, Ohnuma T. Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: Screening for effective target sites. Int J Cancer 1999; 81: 944-950.

Halatsch ME, Botefur IC, Schmidt U, Holland JF, Ohnuma T. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J Neurosurg 2000; 92: 297-305.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Ohnuma during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • Onconova Therapeutics, Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Atran Berg Laboratory Building Room 216
1428 Madison Avenue
New York, NY 10029

Tel: 212-241-9572
Fax: 212-876-5276
Department of Medicine - Oncology

1470 Madison Avenue
3rd floor
New York, NY 10029

Tel: 212-241-6756
Get Directions